Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company's main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; and ophthalmology. The company's marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.
  • TickerBIIB
  • ISINUS09062X1037
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Kenneth Shields ...
  • Laura Chico

Going Over The WATERFALL Results - We Still Think There's A Path Forward

Kenneth Shields ...
  • Laura Chico

When A WATERFALL Beats A MOUNTAIN

Kenneth Shields ...
  • Laura Chico

Weekly Neurology Prescription Sales Tracker -- Week Ending 6/4/21

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weigh...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Small-Caps Testing Critical Resistance; Downgrading Communications As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based advance. There are some developments that leave us wanting more, but we are inching toward an outright bullish outlook. • The Failure of a Bearish Pattern is Bullish. We often know the implied direction (up or down) that a specific chart pattern is likely to resolve based on historical probabilities. But chart patterns are not infallible, and some technicians - present company inclu...

Kenneth Shields ...
  • Laura Chico

Going Over The WATERFALL Results - We Still Think There's A Path Forward

Kenneth Shields ...
  • Laura Chico

When A WATERFALL Beats A MOUNTAIN

Kenneth Shields ...
  • Laura Chico

Weekly Neurology Prescription Sales Tracker -- Week Ending 6/4/21

Kenneth Shields ...
  • Laura Chico

If You Build It, Will They Come? We're Still Skeptical

Kenneth Shields ...
  • Laura Chico

So, This Is Actually Happening... Aduhelm (Aducanumab) Approved

Biogen Inc. - March 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Biogen Inc.: Update to credit analysis - Mature MS franchise and recent Alzheimer's setback will prompt M&A

Biogen's leadership positions in MS and spinal muscular atrophy and its strong credit metrics are tempered by a slowing growth outlook and pipeline execution risk.

Biogen Inc. - December 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's announces completion of a periodic review of ratings of Biogen Inc.

Announcement: Moody's announces completion of a periodic review of ratings of Biogen Inc.. Global Credit Research- 15 Feb 2019. New York, February 15, 2019-- Moody's Investors Service has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit.

Biogen Inc. - September 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BIOGEN reduced its risk exposure resulting in an upgrade to Slightly Positive

BIOGEN (US), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 1 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date April 30, 2021, the closing price was USD 267.33 and its potential was estimated at USD 339.00.

Dominic Rose ...
  • Naresh Chouhan

Global CDMOs - Impact of Alzheimer's Windfall

Our unique coverage of the biggest CDMO’s allows us to quantify the financial impact on the industry of a potential Alzheimer’s windfall from Biogen’s aducanumab. As the FDA filing draws closer, Biogen are likely to be involved in intense negotiations to find alternative sources of supply. Our highly detailed analysis shows how much aducanumab will need to be produced, who the winners are likely to be, the revenue uplift they may enjoy and the NPV uplift to each player. Lonza & Samsung Biologics are likely the biggest winners with Catalent close behind.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch